Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients

Journal of Clinical Oncology

Volumn 18, Issue 13, 2000, Pages 2603-2606

  Zinzani, Pier Luigi ^a   Baliva, Gianandrea ^a   Magagnoli, Massimo ^a   Bendandi, Maurizio ^a   Modugno, Gino ^a   Gherlinzoni, Filippo ^a   Orcioni, Giulio Fraternali ^a   Ascani, Stefano ^a   Simoni, Romeo ^a   Pileri, Stefano A ^a   Tura, Sante ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETREATMENT; SKIN LYMPHOMA; T CELL LYMPHOMA; THROMBOCYTOPENIA;

EID: 0033934870     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.13.2603     Document Type: Article

References (25)

1. Corradini P, Astolfi M, Cherasco C, et al: Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 89:724-731, 1997
2. Gianni AM, Bregni M, Siena S, et al: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
4. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
5. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995
6. Kaminski M, Zasadny K, Francis IR, et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981, 1996
7. Harris N, Jaffe E, Stein H, et al: A revised European-American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
8. Winkler CF, Sausville EA, Ihde DC, et al: Combined modality treatment of cutaneous T cell lymphoma: Results of a 6-year follow-up. J Clin Oncol 4:1094-1100, 1986
9. Ascani S, Zinzani PL, Gherlinzoni F, et al: Peripheral T-cell lymphomas: Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Ann Oncol 8:583-592, 1997
10. Ansell SM, Habermann TM, Kurtin PJ, et al: Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 15:2296-2301, 1997
11. 389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 39:63-73, 1998
12. Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 17:3117-3121, 1999
13. Polplin EAD, Corbett T, Flaherty L, et al: Difluorodeoxycytidine (dFdC, gemcitabine): A phase I study. Invest New Drugs 10:165-170, 1992
14. Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
15. Storniolo AM, Allerheiligen SRB, Pearce HL: Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 24:S7-2-S7-7, 1997 (suppl 7)
16. International Union Against Cancer (UICC): TNM classification of malignant tumours. New York, NY, Springer-Verlag, 1987
17. Carbone PP, Kaplan HS, Musshoff K: Report of committee on Hodgkin's disease staging classification. Cancer 31:1860-1861, 1971
18. Tesch H, Santoro A, Fiedler F, et al: Phase II study with gemcitabine in patients with Hodgkin's disease: Results of a multicenter study. Blood 90:1514-1518, 1997
19. Fossa A, Santoro A, Hiddemann W, et al: Gemcitabine as single agent in the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). Proc Am Soc Clin Oncol 18:27a, 1999 (abstr 98)
20. Zinzani PL, Magagnoli M, Bendandi M, et al: Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9:1351-1353, 1998
21. Von Hoff DD, Dahlberg S, Hartstock RJ, et al: Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group Study. J Natl Cancer Inst 82:1353-1355, 1990
22. Greiner D, Olsen EA. Petroni G: Pentostatin (2′-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 36:950-955, 1997
23. Huang P, Plunkett W: Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36:181-188, 1995
24. Iwasaki H, Huang P, Keating MJ, et al: Differential incorporation of ara-c, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 90:270-278, 1997
25. Tosi P, Pellacani S. Zinzani PL, et al: In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells. Haematologica 84:794-798, 1999